Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;26(7):481-492.
doi: 10.1007/s11916-022-01057-3. Epub 2022 May 10.

Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments

Yulia Y Orlova  1 , Sandhya Mehla  2 , Abigail L Chua  3
Affiliations
Review

Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments

Yulia Y Orlova et al. Curr Pain Headache Rep. 2022 Jul.

Abstract

Purpose of review: The aim of this review is to aid in choosing safe options when assessing potential risks of acute migraine treatments based on known mechanisms of action and anticipated safety concerns.

Recent findings: Part 1 highlights safety issues associated with commonly used medications to treat acute migraine attacks. Strategies to mitigate cardiovascular and gastrointestinal risks of nonsteroidal anti-inflammatory drugs, evaluation of cardiovascular risks of triptan and ergot alkaloids, and precautions with use of antiemetics and the novel drugs gepants and ditans are discussed to help practitioners in clinical decision-making. When available, we included recommendations from professional societies and data from pharmacovigilance systems. While guidelines on efficacy are available, one must also consider the possible risks and adverse effects of a drug when creating treatment plans.

Keywords: Acute migraine treatment; Ditans; Gepants; Safety.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Curtin F, Schulz P. Assessing the benefit: risk ratio of a drug–randomized and naturalistic evidence. Dialogues Clin Neurosci. 2011;13:183–90. - PubMed - PMC
    1. Ferrari A, Baraldi C, Licata M, Rustichelli C. Polypharmacy Among Headache Patients: A Cross-Sectional Study. CNS Drugs. 2018;32:567–78. - PubMed - PMC
    1. Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20:56. - PubMed - PMC
    1. •• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20. AHS guidelines for an acute treatment of migraine. - PubMed
    1. •• American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59:1–18. Position statement with recommendations for acute and preventive treatment, including novel drugs.

MeSH terms

Substances

LinkOut - more resources